Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion

Macular oedema (retinal vein occlusion) - dexamethasone: review decision - January 2015 information

Macular oedema (retinal vein occlusion) - dexamethasone: appendix A (PDF 77 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: review proposal November 2014 information

Macular oedema (retinal vein occlusion) - dexamethasone: Appendix B - proposal paper presented to the Institutes Guidance Executive (PDF 295 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: Appendix A - provisional matrix of stakeholders (PDF 36 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: equality impact assessment (PDF 69 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: final appraisal determination information

Macular oedema (retinal vein occlusion) - dexamethasone: final appraisal determination document (PDF 248 KB)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 179 KB)

Consultee and commentator comments on the ACD

Allergan cover letter (PDF 193 KB)

Allergen response to ACD (PDF 460 KB)

Allergan additional analysis (PDF 855 KB)

Appendices to the additional analysis (PDF 736 KB)

RNIB ACD comments (PDF 57 KB)

RCO ACD comments (PDF 103 KB)

RCN ACD comments (PDF 51 KB)

NHS Waltham Forest ACD comments (PDF 288 KB)

Comments on the ACD received from the public through the NICE website

NHS Wirrall (PDF 29 KB)

NHS Bradford and Airedale (PDF 46 KB)

Additional ERG critique post ACD by Aberdeen HTA Group (PDF 1.04 MB)

Macular oedema (retinal vein occlusion) - dexamethasone: appraisal consultation

Macular oedema (retinal vein occlusion) - dexamethasone: appraisal consultation document information

Macular oedema (retinal vein occlusion) - dexamethasone: evaluation report

Macular oedema (retinal vein occlusion) - dexamethasone: pre-meeting briefing (PDF 290 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: final scope (PDF 61 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: final matrix (PDF 49 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: manufacturer submissions

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Allergan Pharmaceuticals (PDF 7.87 MB)

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Allergan Pharmaceuticals - additional analyses (PDF 2.67 MB)

Macular oedema (retinal vein occlusion) - dexamethasone: clarification letters

Macular oedema (retinal vein occlusion) - dexamethasone: NICE request to the manufacturer for clarification on their submission (PDF 135 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: Manufacturer's response to NICE's request for clarification (PDF 871 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: non-manufacturer submissions

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) (PDF 60 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) - case study A (PDF 8.6 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) - case study B (PDF 36 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) - case study C (PDF 8.7 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) - case study D (PDF 11 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Royal College of Nursing (PDF 61 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Royal College of Ophthalmologists (PDF 119 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: submission from Royal College of Ophthalmologists - Interim Guidelines for Management of Retinal Vein Occlusion (PDF 287 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statements

Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statement - McLaughlan (PDF 17 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statement - Pearce (PDF 18 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statement - Read (PDF 20 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statement - Taylor (PDF 11 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: evidence review group report

Macular oedema (retinal vein occlusion) - dexamethasone: Evidence Review Group report (PDF 1.47 MB)

Macular oedema (retinal vein occlusion) - dexamethasone: Evidence Review Group report - additional analyses (PDF 158 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: Evidence Review Group report - factual accuracy check (PDF 65 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: final scope (PDF 61 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: final matrix (PDF 48 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: Institute's response to consultee and commentator comments on the draft scope (PDF 186 KB)

Macular oedema (retinal vein occlusion) - dexamethasone: Institute's response to consultee and commentator comments on the draft scope (PDF 43 KB)

Appendix B: draft scope for consultation (pre-referral) (PDF 34 KB)

Appendix C: provisional matrix (pre-referral) (PDF 30 KB)